The U.S. Surgeon General recently issued a call to action to prevent skin cancer. However, screening for melanoma currently is not supported by U.S. Preventive Services Task Force skin cancer screening guidelines. The U.S. Preventive Services Task Force has expressed several concerns regarding population-wide screening for skin cancer, including uncertainty whether screening would reduce deaths, having patients undergo unnecessary tissue biopsies and the cost associated with screening individuals who have a low-risk for developing skin cancer.
In a clinical review published in the Feb. 10 issue of The Journal of the American Medical Association, Moffitt physicians, Sondak and L. Frank Glass, M.D., described data from an Australian melanoma screening study that supports more extensive high-risk population-based screening programs. The Australian researchers gave extensive skin screenings every six months to 311 people who had an increased risk of developing melanoma. They detected 75 melanomas over an average follow-up period of three and a half years, but this was not associated with an excessive number of unnecessary biopsies.
The review article cites a second study in which a German state that initiated a comprehensive skin screening program experienced a 48 percent reduction in melanoma-related deaths after its initiation, whereas the melanoma mortality rate remained unchanged in neighboring states and Denmark. These results prompted a national skin cancer screening program throughout Germany for all people 35 years of age and older.
Moffitt physicians suggest that melanoma screening strategies may be more feasible by focusing on high-risk populations, such as middle-aged and older patients, and using newer diagnostic tools. Screening programs should include efforts to educate the general population about the importance of skin cancer screening. Physicians must also be trained to perform skin examinations and be able to recognize the early stages of melanoma. Special emphasis should be placed on ensuring that patients who are at a high-risk of developing the disease understand the importance of cancer screening, and that they are being examined by experienced dermatologists before developing invasive disease.
About Moffitt Cancer Center
Located in Tampa, Moffitt is one of only 41 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt’s excellence in research, its contributions to clinical trials, prevention and cancer control. Moffitt is the top-ranked cancer hospital in the Southeast and has been listed in U.S. News & World Report’s “Best Hospitals” for cancer care since 1999. With more than 4,500 employees, Moffitt has an economic impact in Florida of nearly $1.6 billion. For more information, visit MOFFITT.org, and follow the Moffitt momentum on Facebook, Twitter and YouTube.